Thorium-227 Radiopharmaceutical Complex Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for targeted radionuclide therapy, particularly using alpha-emitting radionuclides like thorium-227, face challenges in achieving selective cell killing with minimal toxicity to healthy tissues due to the short half-life and instability of radionuclide complexes, leading to unacceptable side effects and limited therapeutic windows.
Innovation Solution
Development of a method to form stable thorium-227 complexes with octadentate chelators conjugated to a tissue-targeting moiety, specifically the HER2 antigen, allowing for rapid and convenient preparation, high specificity, and enhanced stability, enabling effective targeting of cancer cells while minimizing exposure to toxic daughter isotopes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If alpha-emitting radionuclides like thorium-227 are used for targeted radionuclide therapy, then selective cell killing capability is improved, but stability of the radionuclide complex deteriorates leading to toxicity to healthy tissues
Solution Approach 1:
The radionuclide complex is segmented into distinct functional components: an octadentate chelator (which provides stability and binds the radionuclide), a targeting moiety (which provides selective cell killing capability by targeting specific cancer cells), and the alpha-emitting radionuclide thorium-227. This segmentation allows each component to optimize its function independently while maintaining overall complex stability.
Solution Approach 2:
The patent employs a composite radionuclide complex structure combining an octadentate chelator with proven stability characteristics, a targeting moiety for selective cancer cell recognition, and thorium-227 as the alpha-emitting radionuclide. This composite structure resolves the contradiction by ensuring the chelator-radionuclide bond remains stable in circulation while the targeting moiety enables selective delivery to cancer cells, minimizing toxicity to healthy tissues.
2Object-affected harmful factors
If short-lived radionuclides are used for therapy, then radiation dose emission in the body before target site is reached is reduced, but production and distribution difficulty increases
Solution Approach 1:
The patent changes the half-life parameter of the radionuclide from short-lived to thorium-227 with a half-life of 18.7 days. This parameter change enables practical production and distribution while still maintaining effective therapy. The extended half-life allows the radionuclide to be produced at a central facility, distributed to clinical sites, and administered to patients without excessive radiation emission during transit, resolving the contradiction between manufacturability and radiation safety.
3Strength
If alpha-emitting radionuclides are used, then cytotoxicity is enhanced, but control and study of radionuclide distribution requirements increase
Solution Approach 1:
The patent introduces an octadentate chelator as an intermediary between the alpha-emitting radionuclide thorium-227 and the targeting moiety. This intermediary chelator provides a stable coordination environment that controls radionuclide distribution and prevents premature release. The chelator acts as a mediator that maintains the radionuclide in a controlled, stable complex during circulation and delivery, reducing the complexity of control and study requirements while preserving the high cytotoxicity of the alpha-emitter.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables the targeted delivery of thorium-227 with reduced myelotoxicity and improved stability, allowing for effective treatment of various diseases, including cancers, by maintaining the therapeutic window and minimizing side effects, with the complexes demonstrating outstanding stability and radiolysis resistance.
Implementation Method 1
Development of a method to form stable thorium-227 complexes with octadentate chelators
Implementation Method 2
conjugated to a tissue targeting moiety targeting the HER2 antigen
Implementation Method 3
alpha-emitting radionuclides like thorium-227
Data Source
AI summary
The invention provides a method for the formation of a tissue-targeting thorium complex, said method comprising; a) forming an octadentate chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N-position with a methyl group, and a coupling moiety terminating in a carboxylic acid group; b) coupling said octadentate chelator to at least one tissue-targeting moiety targeting HER2; and c) contacting said tissue-targeting chelator with an aqueous solution comprising an ion of at least one alpha-emitting thorium isotope. A method of treatment of a neoplastic or hyperplastic disease comprising admistration of such a tissue-targeting thorium complex, as well as the complex and corresponding pharmaceutical formulations are also provided.